Sign In
Buy ATAI
$4.97
-0.200 (-3.87%)
At Close: Jul 13, 2026
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
03:18pm, Monday, 13'th Jul 2026
The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Je
What This $496,000 Insider Sale at AtaiBeckley Means Amid Roughly 100% Stock Run
07:52pm, Thursday, 09'th Jul 2026
This disposal of 100,000 shares was executed at $4.96 per share, generating gross proceeds of $496,000 on July 7, 2026. The transaction reduced Hershberg direct equity position by 50% through the sale
FuelCell Energy shares fall after company prices upsized $225M stock offering
07:51am, Wednesday, 08'th Jul 2026
FuelCell Energy (NASDAQ:FCEL) shares declined on Wednesday after the company priced an upsized public offering of common stock, raising concerns among...
Dow Jones and Nasdaq start lower as Trump says Iran ceasefire 'over'
06:00am, Wednesday, 08'th Jul 2026
10am: Wall Street starts in the red Wall Street stocks have mostly opened in the red, after government bond yields climbed to around a seven-week high...
AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies
12:56pm, Tuesday, 07'th Jul 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01, according to Jefferies analysts, who highlighted
SharkNinja price target boosted by Bank of America on improving sales trends
11:29am, Tuesday, 07'th Jul 2026
SharkNinja Inc (NYSE:SN.) received a higher price target from Bank of America, which raised its price objective to $165 from $145 and reiterated its 'Buy'...
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
11:10am, Tuesday, 07'th Jul 2026
ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.
AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies
08:47am, Tuesday, 07'th Jul 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01,...
Lockheed Martin to acquire Ultra Maritime for $3.5B
09:28am, Monday, 06'th Jul 2026
Lockheed Martin Corp (NYSE:LMT) said on Monday it has signed a definitive agreement to acquire Ultra Maritime for $3.45 billion, in a move aimed at...
AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4
08:43am, Monday, 06'th Jul 2026
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday that it has completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating investigational therapy VLS-01 for adults wit
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
06:00am, Monday, 06'th Jul 2026
156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VL
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?
12:30pm, Thursday, 02'nd Jul 2026
ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs
12:10pm, Thursday, 02'nd Jul 2026
ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
11:51am, Thursday, 02'nd Jul 2026
ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.
AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish
11:09pm, Tuesday, 30'th Jun 2026
ATAI is now a more focused psychedelics biotech. Particularly, BPL-003 is their main bet on TRD's sizeable TAM. BPL-003 has aligned its research with the FDA's feedback and will proceed with a two-stu
